IBDEI2JB ; ; 17-FEB-2016
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;JUN 29, 2015
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,42998,1,4,0)
 ;;=4^E11.40
 ;;^UTILITY(U,$J,358.3,42998,2)
 ;;=^5002644
 ;;^UTILITY(U,$J,358.3,42999,0)
 ;;=E11.42^^164^2060^98
 ;;^UTILITY(U,$J,358.3,42999,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,42999,1,3,0)
 ;;=3^DM Type 2 w/ DM Polyneuropathy
 ;;^UTILITY(U,$J,358.3,42999,1,4,0)
 ;;=4^E11.42
 ;;^UTILITY(U,$J,358.3,42999,2)
 ;;=^5002646
 ;;^UTILITY(U,$J,358.3,43000,0)
 ;;=E11.43^^164^2060^91
 ;;^UTILITY(U,$J,358.3,43000,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,43000,1,3,0)
 ;;=3^DM Type 2 w/ DM Autonomic Polyneuropathy
 ;;^UTILITY(U,$J,358.3,43000,1,4,0)
 ;;=4^E11.43
 ;;^UTILITY(U,$J,358.3,43000,2)
 ;;=^5002647
 ;;^UTILITY(U,$J,358.3,43001,0)
 ;;=E11.49^^164^2060^93
 ;;^UTILITY(U,$J,358.3,43001,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,43001,1,3,0)
 ;;=3^DM Type 2 w/ DM Neurological Complications
 ;;^UTILITY(U,$J,358.3,43001,1,4,0)
 ;;=4^E11.49
 ;;^UTILITY(U,$J,358.3,43001,2)
 ;;=^5002649
 ;;^UTILITY(U,$J,358.3,43002,0)
 ;;=E11.51^^164^2060^96
 ;;^UTILITY(U,$J,358.3,43002,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,43002,1,3,0)
 ;;=3^DM Type 2 w/ DM Peripheral Angiopathy w/o Gangrene
 ;;^UTILITY(U,$J,358.3,43002,1,4,0)
 ;;=4^E11.51
 ;;^UTILITY(U,$J,358.3,43002,2)
 ;;=^5002650
 ;;^UTILITY(U,$J,358.3,43003,0)
 ;;=E11.52^^164^2060^97
 ;;^UTILITY(U,$J,358.3,43003,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,43003,1,3,0)
 ;;=3^DM Type 2 w/ DM Peripheral Angiopathy w/ Gangrene
 ;;^UTILITY(U,$J,358.3,43003,1,4,0)
 ;;=4^E11.52
 ;;^UTILITY(U,$J,358.3,43003,2)
 ;;=^5002651
 ;;^UTILITY(U,$J,358.3,43004,0)
 ;;=E11.610^^164^2060^94
 ;;^UTILITY(U,$J,358.3,43004,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,43004,1,3,0)
 ;;=3^DM Type 2 w/ DM Neuropathic Arthropathy
 ;;^UTILITY(U,$J,358.3,43004,1,4,0)
 ;;=4^E11.610
 ;;^UTILITY(U,$J,358.3,43004,2)
 ;;=^5002653
 ;;^UTILITY(U,$J,358.3,43005,0)
 ;;=E11.620^^164^2060^92
 ;;^UTILITY(U,$J,358.3,43005,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,43005,1,3,0)
 ;;=3^DM Type 2 w/ DM Dermatitis
 ;;^UTILITY(U,$J,358.3,43005,1,4,0)
 ;;=4^E11.620
 ;;^UTILITY(U,$J,358.3,43005,2)
 ;;=^5002655
 ;;^UTILITY(U,$J,358.3,43006,0)
 ;;=E11.621^^164^2060^99
 ;;^UTILITY(U,$J,358.3,43006,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,43006,1,3,0)
 ;;=3^DM Type 2 w/ Foot Ulcer
 ;;^UTILITY(U,$J,358.3,43006,1,4,0)
 ;;=4^E11.621
 ;;^UTILITY(U,$J,358.3,43006,2)
 ;;=^5002656
 ;;^UTILITY(U,$J,358.3,43007,0)
 ;;=E11.622^^164^2060^104
 ;;^UTILITY(U,$J,358.3,43007,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,43007,1,3,0)
 ;;=3^DM Type 2 w/ Skin Ulcer
 ;;^UTILITY(U,$J,358.3,43007,1,4,0)
 ;;=4^E11.622
 ;;^UTILITY(U,$J,358.3,43007,2)
 ;;=^5002657
 ;;^UTILITY(U,$J,358.3,43008,0)
 ;;=E11.630^^164^2060^103
 ;;^UTILITY(U,$J,358.3,43008,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,43008,1,3,0)
 ;;=3^DM Type 2 w/ Periodontal Disease
 ;;^UTILITY(U,$J,358.3,43008,1,4,0)
 ;;=4^E11.630
 ;;^UTILITY(U,$J,358.3,43008,2)
 ;;=^5002659
 ;;^UTILITY(U,$J,358.3,43009,0)
 ;;=E11.641^^164^2060^101
 ;;^UTILITY(U,$J,358.3,43009,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,43009,1,3,0)
 ;;=3^DM Type 2 w/ Hypoglycemia w/ Coma
 ;;^UTILITY(U,$J,358.3,43009,1,4,0)
 ;;=4^E11.641
 ;;^UTILITY(U,$J,358.3,43009,2)
 ;;=^5002661
 ;;^UTILITY(U,$J,358.3,43010,0)
 ;;=E11.649^^164^2060^102
 ;;^UTILITY(U,$J,358.3,43010,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,43010,1,3,0)
 ;;=3^DM Type 2 w/ Hypoglycemia w/o Coma
 ;;^UTILITY(U,$J,358.3,43010,1,4,0)
 ;;=4^E11.649
 ;;^UTILITY(U,$J,358.3,43010,2)
 ;;=^5002662
 ;;^UTILITY(U,$J,358.3,43011,0)
 ;;=E11.65^^164^2060^100
 ;;^UTILITY(U,$J,358.3,43011,1,0)
 ;;=^358.31IA^4^2
